What is Eclipse

COPD is most commonly caused by smoking and is usually diagnosed based on a history of exposure to risk factors and the presence of airflow limitation that is not fully reversible (as measured by spirometry). However, spirometry only measures one aspect of disease – airway obstruction. Therefore, in order to improve disease understanding and enable the development of more treatment options to optimise management of all aspects of the disease (e.g. muscle dysfunction, mucus hypersecretion, emphysema, dyspnea and cough), better characterisation of the disease entities that make up COPD is required. In addition, identification of more sensitive measures and/or markers of disease progression are also needed.

Learn more about the Study design

and

 Study endpoints.

Design Assessments include:

  • Pulmonary function measurements (plethysmography, spirometry and forced oscillometry)

  • Biomarkers (in blood, sputum, urine, and exhaled breath condensate for proteomic and metabolomic analysis)

  • Health outcomes

  • Chest computed tomography scans

  • Body impedance

  • Resting oxygen saturation

  • 6 minute walk distance

Note: list above is not in any order of importance.

Learn more

Why Eclipse is developed

The ECLIPSE study was therefore designed to determine the underlying mechanisms of disease progression
and identify biomarkers that may serve as surrogate endpoints and therefore measures of disease progression.
ECLIPSE is a unique collaborative project between external experts and industry.

01.

Some Heading

ECLIPSE is the first study to investigate novel endpoints in COPD disease progression.

02.

Some Heading

ECLIPSE will provide a greater insight into patient needs and expand COPD disease understanding – causes, processes, patterns and progression.

03.

Some Heading

The ECLIPSE study is leading the advancement of scientific and medical investigation into COPD.

News

GSK makes ECLIPSE data available to investigators through new research collaboration
GSK and the Channing Division of Network Medicine at the Brigham and Women’s Hospital (BWH) have signed a collaborative research agreement for ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints). Under the agreement, BWH has assumed data coordinating centre functions for ECLIPSE, including the integration of the existing data sets (clinical, physiological, imaging, genetics, and –omics) with recently obtained 8-year survival data and data from the ECLIPSE investigator-led extension study in Europe. The data coordinating centre will provide data sets to investigators with approved ancillary studies in ECLIPSE. In addition, BWH Channing Division will also perform systems biology research and conduct biostatistical data analysis using the ECLIPSE data.

Edwin K. Silverman

Chief of the Channing Division of Network Medicine at BWH

ECLIPSE is a large and well-characterized study population, which has already proven to be extremely useful for studies of COPD epidemiology and genetics. We are pleased to assist the general scientific community in advancing research in COPD through this valuable data set.

Ruth Tal-Singer

Vice President for COPD clinical discovery at GSK

To maximize the value of ECLIPSE we have been sharing data with individual researchers and Consortia including COPDGene, the COPD Biomarker Consortium and U-BIOPRED based on written proposals approved by the Steering and Scientific Committees. Collaboration led to important insights and publications in COPD including the qualification of the biomarker plasma fibrinogen as a drug development tool by the FDA. We hope this will make it easier for interested clinical researchers to access the data from this unique collaborative longitudinal study in COPD.”

GSK makes ECLIPSE data available to investigators through new research collaboration
GSK and the Channing Division of Network Medicine at the Brigham and Women’s Hospital (BWH) have signed a collaborative research agreement for ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints). Under the agreement, BWH has assumed data coordinating centre functions for ECLIPSE, including the integration of the existing data sets (clinical, physiological, imaging, genetics, and –omics) with recently obtained 8-year survival data and data from the ECLIPSE investigator-led extension study in Europe. The data coordinating centre will provide data sets to investigators with approved ancillary studies in ECLIPSE. In addition, BWH Channing Division will also perform systems biology research and conduct biostatistical data analysis using the ECLIPSE data.
Will I be able to upgrade down the road?
Greetings, Exalted One. Allow me to introduce myself. I am Luke Skywalker, Jedi Knight and friend to Captain Solo. I know that you are powerful, mighty Jabba, and that your anger with Solo must be equally powerful. I seek an audience with Your Greatness to bargain for Solo's life. With your wisdom, I'm sure that we can work out an arrangement which will be mutually beneficial and enable us to avoid any unpleasant confrontation.
What's the difference between the Pro plans?
Greetings, Exalted One. Allow me to introduce myself. I am Luke Skywalker, Jedi Knight and friend to Captain Solo. I know that you are powerful, mighty Jabba, and that your anger with Solo must be equally powerful. I seek an audience with Your Greatness to bargain for Solo's life. With your wisdom, I'm sure that we can work out an arrangement which will be mutually beneficial and enable us to avoid any unpleasant confrontation.
Can I cancel my membership at anytime?
Greetings, Exalted One. Allow me to introduce myself. I am Luke Skywalker, Jedi Knight and friend to Captain Solo. I know that you are powerful, mighty Jabba, and that your anger with Solo must be equally powerful. I seek an audience with Your Greatness to bargain for Solo's life. With your wisdom, I'm sure that we can work out an arrangement which will be mutually beneficial and enable us to avoid any unpleasant confrontation.